Acasti Pharma Inc (NAS:ACST)

$ 3.3 0.15 (4.76%) Market Cap: 31.02 Mil Enterprise Value: 5.93 Mil PE Ratio: 0 PB Ratio: 0.48 GF Score: 41/100

Acasti Pharma Inc KOL Event Transcript
Oct 11, 2023
Acasti Pharma Inc Annual Shareholders Meeting Transcript
Oct 10, 2023
Acasti Pharma Inc at Lytham Partners Spring Investor Conference (Virtual) Transcript
May 18, 2023
Acasti Pharma Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Q3 2023 Acasti Pharma Inc Earnings Call Transcript
Feb 14, 2023

$3.99 (+3.28%)

Earnings
Acasti Pharma Inc GTX-101 and GTX-102 Call Transcript
Jan 10, 2023
Q2 2023 Acasti Pharma Inc Earnings Call Transcript
Nov 14, 2022

$3.12 (+3.38%)

Earnings
Q1 2023 Acasti Pharma Inc Earnings Call Transcript
Aug 11, 2022

$5.4 (+1.35%)

Earnings
Q4 2022 Acasti Pharma Inc Earnings Call Transcript
Jun 21, 2022

$5.59 (+0.12%)

Earnings
Acasti Pharma Inc Announces Positive Results for Pharmacokinetic Bridging Study Call Transcript
May 18, 2022
Acasti Pharma Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 28, 2022
Q3 2022 Acasti Pharma Inc Earnings Call Transcript
Feb 14, 2022

$7.32 (+7.02%)

Earnings
Q2 2022 Acasti Pharma Inc Earnings Call Transcript
Nov 10, 2021

$10.02 (-1.18%)

Earnings
Acasti Pharma Inc Planned Acquisition of Grace Therapeutics Inc Call Transcript
Aug 04, 2021
Acasti Pharma Inc Annual Shareholders Meeting Transcript
Sep 30, 2020
Q4 2020 Acasti Pharma Inc Earnings Call Transcript
Jun 29, 2020

$22.76 (-14.58%)

Earnings
Q3 2020 Acasti Pharma Inc Earnings Call Transcript
Feb 14, 2020

$27.36 (-1.55%)

Earnings
Q2 2020 Acasti Pharma Inc Earnings Call Transcript
Nov 13, 2019

$98.88 (-3.29%)

Earnings
Q1 2020 Acasti Pharma Inc Earnings Call Transcript
Aug 14, 2019

$98.4 (+6.22%)

Earnings
Q4 2019 Acasti Pharma Inc Earnings Call Transcript
Jun 26, 2019

$57.6 (+14.29%)

Earnings

Q2 2022 Acasti Pharma Inc Earnings Call Transcript

Nov 10, 2021 / 06:00PM GMT

Release Date Price: $10.02 (-1.18%)

Transcript 8-K10-Q

Operator

Good day, ladies and gentlemen, and welcome to the Acasti Pharma Second Quarter 2022 Earnings Call. (Operator Instructions) It is now my pleasure to turn the floor over to your host, David Waldman of Investor Relations. Sir, the floor is yours.

David K. Waldman

Crescendo Communications, LLC - President & CEO

Thank you, and good afternoon, everyone. I'd like to welcome you to Acasti Pharma's Fiscal 2022 Second Quarter Conference Call. On the call with us this afternoon are Jan D'Alvise, President and CEO; Dr. Pierre Lemieux, Chief Operating Officer, Canada; Chief Scientific Officer and Co-Founder; Dr. George Kottayil, Chief Operating Officer, U.S.; Brian Ford, Chief Financial Officer; and Prashant Kohli VP of Commercial Operations.

We are planning for a Q&A session at the end of our prepared remarks. But if you have any remaining questions after the call or would like any additional information about the company, please contact Crescendo Communications at (212) 671-1020. I'd also like to remind everyone that statements on this conference call

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.